Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi; Hirao, Makoto; Miyama, Akira; Nakaya, Hiroyuki; Tsuji, Shigeyoshi; Takahi, Koichiro; Tsuboi, Hideki; Okamura, Gensuke; Etani, Yuki; Takami, Kenji; Yoshikawa, Hideki

doi:https://doi.org/10.1080/14397595.2020.1769895

Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi et al.

Modern Rheumatology, 2021, 31(2), 485-492

Number of Access:1,399（2025-09-03 11:38 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93250

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
ModRheumatol_31_2_485	pdf	None	2.02 MB	67	2023.12.07

Creative Commons : Attribution - NonCommercial

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, Kosuke
	NRID 1000040237938 1000040237938 CreatorName Hashimoto, Jun
	NRID 1000000576910 1000000576910 CreatorName Kashii, Masafumi
	NRID 1000010527708 1000010527708 CreatorName Hirao, Makoto
	CreatorName Miyama, Akira
	CreatorName Nakaya, Hiroyuki
	CreatorName Tsuji, Shigeyoshi
	CreatorName Takahi, Koichiro
	CreatorName Tsuboi, Hideki
	CreatorName Okamura, Gensuke
	NRID 1000060898930 1000060898930 CreatorName Etani, Yuki
	CreatorName Takami, Kenji
	NRID 1000060191558 1000060191558 CreatorName Yoshikawa, Hideki
Subject	Bisphosphonate
	denosumab
	discontinuation
	follow-on treatment
	postmenopausal osteoporosis
Description	Ebina K., Hashimoto J., Kashii M., et al. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Modern Rheumatology 31, 485 (2021); https://doi.org/10.1080/14397595.2020.1769895.
Abstract	Objectives: To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation. Methods: In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) (n = 26) or teriparatide (TPTD) (n = 27) were switched to DMAb (administered 2.6 times), and then discontinued. Patients (73.1 years, T-scores of the lumbar spine [LS] − 2.7 and femoral neck [FN] − 2.2) were switched to either (1) raloxifene (RAL) (n = 13) or BP [(2) weekly or monthly BP (wmBP) (n = 29) or (3) zoledronate (ZOL) (n = 11)], based on each physician’s decision (mean interval after final DMAb administration was 7.2 months). Bone mineral density (BMD) at final DMAb administration were set as baseline. Results: Changes in LS BMD at 1.5 years after final DMAb administration were −2.7% in the RAL, 0.7% in the wmBP, and 1.9% in the ZOL (p =.31 between groups), and in FN BMD were −3.8%, −0.8%, and 1.8%, respectively (p =.02 between the RAL and ZOL; p =.048 between the RAL and BP). Clinical vertebral fracture incidence during 1.5 years after final DMAb administration was 23.1% in the RAL, 3.4% in the wmBP, and 0.0% in the ZOL (p =.048 between the RAL and ZOL; p =.015 between the RAL and BP). No significant differences were observed in these parameters between the wmBP and ZOL. Conclusion: These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.
Publisher	Taylor and Francis Ltd.
Source Title	Modern Rheumatology
Volume (Issue)	31(2)
Page	485-492
Date of Issued	2021-03-04
Language	English
Handle URL	https://hdl.handle.net/11094/93250
PISSN	14397595
eISSN	14397609
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1080/14397595.2020.1769895
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Modern Rheumatology. 2021, 31(2), p. 485-492
DC.title	Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
DC.creator	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Miyama, Akira
	Nakaya, Hiroyuki
	Tsuji, Shigeyoshi
	Takahi, Koichiro
	Tsuboi, Hideki
	Okamura, Gensuke
	Etani, Yuki
	Takami, Kenji
	Yoshikawa, Hideki
DC.publisher	Taylor and Francis Ltd.
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2021-03-04
DC.identifier	https://doi.org/10.1080/14397595.2020.1769895
DC.subject	Bisphosphonate
	denosumab
	discontinuation
	follow-on treatment
	postmenopausal osteoporosis
DC.description	Ebina K., Hashimoto J., Kashii M., et al. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Modern Rheumatology 31, 485 (2021); https://doi.org/10.1080/14397595.2020.1769895.
DCTERMS.abstract	Objectives: To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation. Methods: In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) (n = 26) or teriparatide (TPTD) (n = 27) were switched to DMAb (administered 2.6 times), and then discontinued. Patients (73.1 years, T-scores of the lumbar spine [LS] − 2.7 and femoral neck [FN] − 2.2) were switched to either (1) raloxifene (RAL) (n = 13) or BP [(2) weekly or monthly BP (wmBP) (n = 29) or (3) zoledronate (ZOL) (n = 11)], based on each physician’s decision (mean interval after final DMAb administration was 7.2 months). Bone mineral density (BMD) at final DMAb administration were set as baseline. Results: Changes in LS BMD at 1.5 years after final DMAb administration were −2.7% in the RAL, 0.7% in the wmBP, and 1.9% in the ZOL (p =.31 between groups), and in FN BMD were −3.8%, −0.8%, and 1.8%, respectively (p =.02 between the RAL and ZOL; p =.048 between the RAL and BP). Clinical vertebral fracture incidence during 1.5 years after final DMAb administration was 23.1% in the RAL, 3.4% in the wmBP, and 0.0% in the ZOL (p =.048 between the RAL and ZOL; p =.015 between the RAL and BP). No significant differences were observed in these parameters between the wmBP and ZOL. Conclusion: These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	93250
citation_title	Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
citation_author	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Miyama, Akira
	Nakaya, Hiroyuki
	Tsuji, Shigeyoshi
	Takahi, Koichiro
	Tsuboi, Hideki
	Okamura, Gensuke
	Etani, Yuki
	Takami, Kenji
	Yoshikawa, Hideki
citation_publisher	Taylor and Francis Ltd.
citation_language	English
citation_date	2021-03-04
citation_journal_title	Modern Rheumatology
citation_volume	31
citation_issue	2
citation_firstpage	485
citation_lastpage	492
citation_doi	https://doi.org/10.1080/14397595.2020.1769895
citation_public_url	https://hdl.handle.net/11094/93250

Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

Link to primary information

Item Information

Show details